Ted M. Diehl
Vice President, Commercial Oncology at Massive Bio- Claim this Profile
Click to upgrade to our gold package
for the full feature experience.
Topline Score
Bio
Mike Rossi
Ted is a consummate professional and a true colleague. Goal-oriented and persistent, Ted always has the team's back. He brought great value to the Sema4 organization and was driving projects that were innovative and potentially transformative. It was my great pleasure to have worked with him and would do so again without hesitation.
Jay Cascio, RPh, LBC
As VP of Sales, I was able to depend on Ted's commercial strategies within clinical oncology. His comprehensive leadership of commercial strategy allowed for acceptance of our clinical diagnostic test using WES/WTS. These were innovative strategies that Ted was able to present business rationale to our commercial leaders for acceptance. Working as an innovative team and strategic leader his models included guideline executives, medical society executives, patients and patient advocacy groups, policy leaders, key opinion leaders and researchers. He works to include all internal leaders with his strategies. Building on opportunities he last co-led a project with a clinical foundation that will seek to commercialize a first to market cancer diagnostic test. Highly recommend Ted!
Mike Rossi
Ted is a consummate professional and a true colleague. Goal-oriented and persistent, Ted always has the team's back. He brought great value to the Sema4 organization and was driving projects that were innovative and potentially transformative. It was my great pleasure to have worked with him and would do so again without hesitation.
Jay Cascio, RPh, LBC
As VP of Sales, I was able to depend on Ted's commercial strategies within clinical oncology. His comprehensive leadership of commercial strategy allowed for acceptance of our clinical diagnostic test using WES/WTS. These were innovative strategies that Ted was able to present business rationale to our commercial leaders for acceptance. Working as an innovative team and strategic leader his models included guideline executives, medical society executives, patients and patient advocacy groups, policy leaders, key opinion leaders and researchers. He works to include all internal leaders with his strategies. Building on opportunities he last co-led a project with a clinical foundation that will seek to commercialize a first to market cancer diagnostic test. Highly recommend Ted!
Mike Rossi
Ted is a consummate professional and a true colleague. Goal-oriented and persistent, Ted always has the team's back. He brought great value to the Sema4 organization and was driving projects that were innovative and potentially transformative. It was my great pleasure to have worked with him and would do so again without hesitation.
Jay Cascio, RPh, LBC
As VP of Sales, I was able to depend on Ted's commercial strategies within clinical oncology. His comprehensive leadership of commercial strategy allowed for acceptance of our clinical diagnostic test using WES/WTS. These were innovative strategies that Ted was able to present business rationale to our commercial leaders for acceptance. Working as an innovative team and strategic leader his models included guideline executives, medical society executives, patients and patient advocacy groups, policy leaders, key opinion leaders and researchers. He works to include all internal leaders with his strategies. Building on opportunities he last co-led a project with a clinical foundation that will seek to commercialize a first to market cancer diagnostic test. Highly recommend Ted!
Mike Rossi
Ted is a consummate professional and a true colleague. Goal-oriented and persistent, Ted always has the team's back. He brought great value to the Sema4 organization and was driving projects that were innovative and potentially transformative. It was my great pleasure to have worked with him and would do so again without hesitation.
Jay Cascio, RPh, LBC
As VP of Sales, I was able to depend on Ted's commercial strategies within clinical oncology. His comprehensive leadership of commercial strategy allowed for acceptance of our clinical diagnostic test using WES/WTS. These were innovative strategies that Ted was able to present business rationale to our commercial leaders for acceptance. Working as an innovative team and strategic leader his models included guideline executives, medical society executives, patients and patient advocacy groups, policy leaders, key opinion leaders and researchers. He works to include all internal leaders with his strategies. Building on opportunities he last co-led a project with a clinical foundation that will seek to commercialize a first to market cancer diagnostic test. Highly recommend Ted!
Credentials
-
Certified Medical Representative, UMDNJ
University of Medicine & Dentistry of New Jersey (UMDNJ) -
The Five Most Important Questions You Will Ever Ask About Your Organization (Blinkist Summary)
LinkedIn
Experience
-
Massive Bio
-
United States
-
Hospitals and Health Care
-
1 - 100 Employee
-
Vice President, Commercial Oncology
-
Feb 2023 - Present
With the leadership team, develop the commercial strategies and team that lead Massive Bio clinical trial management advancements into clinical oncology. Scale Massive Bio solutions to meet commercial revenue goals. With the leadership team, develop the commercial strategies and team that lead Massive Bio clinical trial management advancements into clinical oncology. Scale Massive Bio solutions to meet commercial revenue goals.
-
-
-
Sema4
-
United States
-
Biotechnology Research
-
200 - 300 Employee
-
Director, Patient Advocacy & Foundations, Oncology Dx
-
Jun 2021 - Oct 2022
Commercial leader within the medical science team. Led the development of oncology strategies for Sema4 with pharma, medical societies, patient foundations, research co-ops, payers, and cancer programs. Initiated oncology collaborations with NCCN, ASCO and ACCC for clinical utility, access and reimbursement. Last led Sema4 to combine scDNA and scRNA to develop a commercial assay for all tumors. Patient Group Collaboration: MMRF, FORCE, ZERO, ACS, CCA, F!ght CRC, BC.org, Komen, LUNGevity, etc. Built team with designated leadership responsibilities for continuance of divisional success. Single Cell Project: • Developed key partnerships between a research foundation and two device companies to present a CLIA/NYS-DOH assay; gained approvals through external and internal C-Suites, including CEOs and Board Members (MMRF, 10X, MissionBio, and Sema4).
-
-
-
IBM
-
IT Services and IT Consulting
-
1 - 100 Employee
-
Strategic Partnering Executive, Oncology Bix
-
Jan 2018 - Jul 2020
Clinical partnership leader for the commercial development of IBM Watson’s new AI and NLP technologies for oncology in leading medical organizations, research groups, and patient foundations. • Presented new commercial oncology strategy/plan to GM and gained approval. • Led and trained a team through commercial partnership strategies. • Developed effectiveness with targeting oncology leadership, leading to >12 academic and community cancer programs contracting with IBM AI/NLP technologies.
-
-
-
Genomic Health
-
United States
-
Biotechnology Research
-
100 - 200 Employee
-
Strategic Market Manager, Oncology Dx
-
Jan 2009 - Jan 2018
Developed a new market for genomic biomarker testing in oncology as commercial and strategic leader. Directed alliance building within industry organizations for clinical acceptance and for patient accessibility to the GHI product portfolio, including fostering relationships with key industry executives, patient foundations, national leading clinics and securing guidelines. • Developed multiple national commercial strategies and market messages and led several ASCO publications in Oncotype DX implications, gained acceptance of current NCCN guideline wording and collaborate with patient foundations. • Developed Oncotype DX from innovation to clinical standard of care and current NCCN guideline verbiage.
-
-
-
Sanofi
-
France
-
Pharmaceutical Manufacturing
-
700 & Above Employee
-
Oncology Therapeutic Executive, Oncology Rx
-
Feb 2002 - Jan 2009
Commercial leader: clinical adoption, team training, and brand marketing for oncology Business Unit, Taxotere. Development Taxotere to clinical standard of care in Breast, Prostate, Head and Neck, and NSCL cancers Commercial leader: clinical adoption, team training, and brand marketing for oncology Business Unit, Taxotere. Development Taxotere to clinical standard of care in Breast, Prostate, Head and Neck, and NSCL cancers
-
-
-
-
Sales Specialist, Gastroenterology Rx
-
Nov 1999 - Feb 2002
Philadelphia Gastroenterology Hospital Specialists that led Prevacid (lanzoprazole) to a clinical standard of care. Philadelphia Gastroenterology Hospital Specialists that led Prevacid (lanzoprazole) to a clinical standard of care.
-
-
Education
-
Liberty University
Master of Arts - MA, Executive Leadership -
Immaculata University
Bachelor of Arts - BA, Organizational Leadership -
Immaculata University
Bachelor of Arts - BA, Human Resources Management/Personnel Administration, General
Community
